Holen Sie sich die Stockscreener-App
96.07
0.92%
-0.89
Schlusskurs vom Vortag:
$96.96
Offen:
$97.53
24-Stunden-Volumen:
1.15M
Relative Volume:
0.64
Marktkapitalisierung:
$19.12B
Einnahmen:
$5.14B
Nettoeinkommen (Verlust:
$1.29B
KGV:
15.00
EPS:
6.4034
Netto-Cashflow:
$1.33B
1W Leistung:
+0.15%
1M Leistung:
+0.05%
6M Leistung:
+14.64%
1J Leistung:
+74.13%
1-Tages-Spanne:
$95.41
$97.57
1-Wochen-Bereich:
$93.23
$97.58
52-Wochen-Spanne:
$55.11
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
96.07 | 19.12B | 5.14B | 1.29B | 1.33B | 6.4034 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp stock: What investors should know about its biotech potential now - AD HOC NEWS
Incyte to Report First Quarter 2026 Financial Results - BioSpace
L2 Asset Management, LLC's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corporation (INCY) stock price, news, quote and history - Yahoo Finance UK
Incyte to Report First Quarter Financial Results - Yahoo Finance
Barclays Maintains Overweight on Incyte Corporation (INCY) March 24, 2026 - Meyka
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data - MyChesCo
Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL - Barchart.com
Incyte Names Cagnoni President, Announces Leadership Changes - MyChesCo
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology CollaborationHas The Bull Case Changed? - Yahoo Finance
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Incyte reports strong 54-week data from late-stage skin disorder study - MSN
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp (INCY) board rep logs 421-share RSU fee grant - Stock Titan
Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees - Stock Titan
Incyte (INCY) director takes 265-share board fee in stock - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Yahoo Finance
Citizens reiterates Incyte stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - MarketBeat
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte Corporation (INCY) Announces Board Member Resignation - GuruFocus
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView — Track All Markets
Incyte (INCY) Board member Susanne Schaffert to step down April 15, 2026 - Stock Titan
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - Yahoo Finance
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Incyte Corp-Aktie (INCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, R&D |
Mar 17 '26 |
Sale |
94.24 |
18,667 |
1,759,178 |
234,800 |
0.95%
3.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):